查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1831918

胃輕癱藥物市場報告（按疾病類型、藥物類別、配銷通路和地區）2025-2033

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球胃輕癱藥物市場規模達67億美元。展望未來， IMARC Group預計到2033年，市場規模將達到98億美元，2025-2033年期間的複合年成長率（CAGR）為4.06%。糖尿病性胃輕癱盛行率的上升、藥物開發技術的進步、醫護人員和患者認知度的提高、醫療保健投資的蓬勃發展、臨床試驗的增多、糖尿病和帕金森氏症等慢性疾病的激增以及監管支持，都是推動市場成長的一些因素。

胃輕癱藥物市場趨勢：

胃輕癱盛行率不斷上升

胃輕癱盛行率的不斷上升，尤其是在糖尿病患者中，正在加速市場成長。 2021年，印度約有7,490萬20至79歲的糖尿病患者，預計2045年將達到1.249億人。此外，糖尿病患者數量的增加也催生了對高效治療和管理的需求，這進一步推動了市場的成長。此外，主要製藥公司正在積極開發新的標靶治療方案，這進一步為市場創造了積極的前景。

藥物開發技術的進步

不斷成長的在研產品數量以及新產品的開發正在促進市場成長。此外，為提高胃輕癱治療的有效性和安全性，藥物研發 (R&D) 投資的激增也推動了市場成長。胃輕癱藥物市場近期的機會，例如高通量篩選、計算和個人化醫療的出現，使得能夠精準快速地識別潛在候選藥物，正在為市場成長提供動力。此外，緩釋製劑和新型給藥機制等藥物傳遞系統的進步，使得藥物的給藥和吸收更加高效，從而推動了市場成長。

醫療保健專業人員和患者的意識不斷提高

醫療保健專業人員和患者對胃輕癱的認知不斷提高，大大促進了市場成長。隨著認知度的提高，患者的診斷更加準確，這進一步推動了市場成長。此外，胃腸病學家等醫療保健專業人員對胃輕癱症狀的認知也越來越敏銳，這有助於更早地識別胃輕癱，從而更好地照顧患者。此外，患者對胃輕癱症狀和治療的認知不斷提高，以及新型治療方案的出現，也推動了胃輕癱藥物的需求。

胃輕癱藥物市場細分：

依疾病類型分類：

  • 糖尿病性胃輕癱
  • 特發性胃輕癱
  • 術後胃輕癱
  • 其他

特發性胃輕癱佔大部分市場佔有率

特發性胃輕癱細分市場的發展源於人們對該疾病影響的日益認知以及對有效治療方案的需求。特發性胃輕癱無法確定根本病因，由於其難以預測的性質和嚴重程度，給患者和醫療保健提供者帶來了巨大的挑戰。臨床醫師對特發性胃輕癱的認知和理解不斷提高，診斷更加精準，並更加重視開發標靶治療。診斷技術的進步，例如影像學和運動功能測試的改進，正在增強識別特發性胃輕癱病例並將其與其他胃腸道疾病區分開來的能力，從而促進胃輕癱藥物市場的成長。此外，針對特發性胃輕癱的研究經費和臨床試驗的增加，正在推動藥物開發的創新，帶來新的治療方案。

按毒品類別分類：

  • 促動力劑
  • 止吐藥
  • 肉毒桿菌注射

促動力劑佔據產業最大佔有率

胃輕癱藥物市場的促動力藥物細分市場受多種關鍵因素驅動，例如胃輕癱盛行率的不斷上升，尤其是在糖尿病患者和老年人群中，這帶來了對有效促動力藥物的強勁需求。促動力藥物可以增強胃動力並促進胃排空，對於控制胃輕癱症狀（包括噁心和嘔吐）至關重要。藥物研發領域的重大進展帶來了促動力藥物製劑的改進，這些製劑療效更佳、副作用更少，從而推動了胃輕癱藥物市場的收入成長。正在進行的促動力藥物研究和臨床試驗有助於更好地了解其作用機制和潛在益處，從而拓展其臨床應用。此外，醫護人員和患者對胃輕癱的認知不斷提高，這凸顯了對有效治療的需求，這進一步推動了對促動力藥物的需求。

按配銷通路細分：

  • 醫院和診所
  • 藥局
  • 網路商店

醫院和診所是主要的細分市場

胃輕癱藥物市場的醫院和診所細分市場，受日益成長的專科醫療護理和先進胃輕癱治療方案需求的驅動。胃輕癱盛行率不斷上升，尤其是在糖尿病患者中，需要更全面、更頻繁的醫療干預，也推動了該細分市場的發展。醫院和診所提供一系列診斷和治療服務，包括專業的胃腸病科室和先進的影像技術，這些對於胃輕癱的準確診斷和有效管理至關重要。此外，糖尿病和帕金森氏症等慢性疾病的發生率上升，這些疾病通常會導致胃輕癱，進一步推動了住院治療的需求。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據胃輕癱藥物最大市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是胃輕癱藥物最大的區域市場。

北美地區市場受胃輕癱盛行率迅速上升的驅動，尤其是在糖尿病族群中，顯著影響了對有效治療的需求。糖尿病的高發生率是導致胃輕癱的主要因素，因為糖尿病性胃輕癱是常見的併發症。此外，胃輕癱藥物市場近期的發展和進步，例如高通量篩選和新型給藥系統，提高了胃輕癱藥物的療效和安全性，有助於市場擴張。此外，該地區還受益於強大的醫療基礎設施和在研發方面的大量投資，從而能夠更快地推出創新療法。此外，醫護人員和患者對胃輕癱及其管理的認知不斷提高，這也促進了市場的成長，從而促進了早期診斷和更積極的治療方法。

本報告回答的關鍵問題

  • 2024 年全球胃輕癱藥物市場規模是多少
  • 2025-2033年全球胃輕癱藥物市場的預期成長率是多少
  • COVID-19 對全球胃輕癱藥物市場有何影響
  • 推動全球胃輕癱藥物市場的關鍵因素有哪些
  • 根據疾病類型，全球胃輕癱藥物市場如何分佈
  • 根據藥物類別，全球胃輕癱藥物市場如何分佈
  • 根據配銷通路，全球胃輕癱藥物市場如何分佈
  • 全球胃輕癱藥物市場的主要區域有哪些
  • 全球胃輕癱藥物市場的主要參與者/公司有哪些

本報告回答的關鍵問題

  • 2024年全球胃輕癱藥物市場規模？ 2025-2033年全球胃輕癱藥物市場的預期成長率為何？
  • COVID-19 對全球胃輕癱藥物市場有何影響？
  • 推動全球胃輕癱藥物市場發展的關鍵因素有哪些？
  • 根據疾病類型，全球胃輕癱藥物市場是如何分佈的？
  • 根據藥物類別，全球胃輕癱藥物市場是如何分佈的？
  • 根據配銷通路，全球胃輕癱藥物市場分佈如何？
  • 全球胃輕癱藥物市場的主要地區有哪些？
  • 全球胃輕癱藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球胃輕癱藥物市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依疾病類型

  • 糖尿病性胃輕癱
  • 特發性胃輕癱
  • 術後胃輕癱
  • 其他

第7章：市場區隔：依藥品類別

  • 促動力劑
  • 止吐藥
  • 肉毒桿菌注射

第8章：市場區隔：按配銷通路

  • 醫院和診所
  • 藥局
  • 網路商店

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 10 章：SWOT 分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
Product Code: SR112025A4608

The global gastroparesis drugs market size reached USD 6.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.06% during 2025-2033. The rising prevalence of diabetic gastroparesis, advancements in drug development technologies, increasing awareness among healthcare professionals and patients, burgeoning healthcare investments, growing clinical trials, surging chronic conditions like diabetes and Parkinson's, and regulatory support are some of the factors propelling the market growth

Gastroparesis Drugs Market Trends:

Increasing Prevalence of Gastroparesis

The escalating prevalence of gastroparesis, especially in diabetes patients, is accelerating the market growth. In 2021 India had about 74.9 million people with diabetes aged between 20-79, which is expected to reach 124.9 million by 2045. Moreover, the increasing number of patients with diabetes has burgeoned the need for efficient treatment and management, which is further providing a considerable thrust to the market growth. Additionally, the key pharmaceutical companies are actively working to develop new and targeted therapy options, which is further creating a positive outlook for the market.

Advancements in Drug Development Technologies

The growing number of products in the pipeline and the development of new product variants are augmenting the market growth. Furthermore, the surging investments in pharmaceutical research and development (R&D) to improve the efficacy and safety of gastroparesis therapies are fueling the market growth. The gastroparesis drugs market recent opportunities, such as the advent of high-throughput screening, computational and personalized medicine, enabling precise and quick identification of potential candidates are providing an impetus to the market growth. Apart from this, the advancements in drug delivery systems, such as extended-release formulations and novel drug-delivery mechanisms, are rendering an efficient administration and absorption of medications, thereby impelling the market growth.

Rising Awareness Among Healthcare Professionals and Patients

The growing awareness among both healthcare professionals and patients regarding gastroparesis is significantly facilitating the market growth. Patients with the condition are more accurately diagnosed due to the subsequent increase in awareness, which further provides a considerable thrust to the market growth. Additionally, healthcare professionals, such as gastroenterologists, are becoming more acutely aware of the symptoms, which further helps recognize gastroparesis sooner, leading to better patient care. Moreover, burgeoning patient awareness about the symptoms and treatment of gastroparesis and the availability of novel treatment options are propelling the gastroparesis drugs demand.

Gastroparesis Drugs Market Segmentation:

Breakup by Disease Type:

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Idiopathic gastroparesis accounts for the majority of the market share

The idiopathic gastroparesis segment is driven by the growing recognition of the condition's impact and the need for effective treatment solutions. Idiopathic gastroparesis, where no underlying cause can be identified, poses significant challenges for patients and healthcare providers due to its unpredictable nature and severity. Increased awareness and understanding of idiopathic gastroparesis among clinicians are leading to more accurate diagnoses and a focus on developing targeted therapies. Advances in diagnostic technologies, such as improved imaging and motility testing, are enhancing the ability to identify idiopathic gastroparesis cases and differentiate them from other gastrointestinal disorders, thereby boosting the gastroparesis drugs market growth. Furthermore, the rise in research funding and clinical trials dedicated to idiopathic gastroparesis is driving innovation in drug development, leading to new therapeutic options.

Breakup by Drug Class:

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Prokinetic agents hold the largest share of the industry

The prokinetic agents segment in the gastroparesis drugs market is driven by several key factors, such as the increasing prevalence of gastroparesis, particularly among diabetic and elderly populations, which creates a strong demand for effective prokinetic therapies. Prokinetic agents, which enhance gastric motility and facilitate stomach emptying, are essential in managing the symptoms of gastroparesis, including nausea and vomiting. Significant advancements in drug development leading to improved prokinetic formulations with enhanced efficacy and fewer side effects are boosting gastroparesis drugs market revenue. The ongoing research and clinical trials focused on prokinetic agents contribute to a better understanding of their mechanisms and potential benefits, thereby expanding their clinical applications. Additionally, the growing awareness of gastroparesis among healthcare professionals and patients underscores the need for effective treatments, further driving the demand for prokinetic agents.

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Pharmacies
  • Online Stores

Hospitals and clinics represent the leading market segment

The hospitals and clinics segment in the gastroparesis drugs market is driven by the increasing demand for specialized medical care and advanced treatment options for managing gastroparesis. The segment benefits from the escalating prevalence of gastroparesis, particularly among diabetic patients, necessitating more comprehensive and frequent medical interventions. Hospitals and clinics offer a range of diagnostic and therapeutic services, including specialized gastroenterology departments and advanced imaging technologies, which are crucial for accurate diagnosis and effective management of gastroparesis. Additionally, the rise in chronic conditions such as diabetes and Parkinson's disease, which often lead to gastroparesis, further drives the need for hospital-based treatments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest gastroparesis drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for gastroparesis drugs.

The North America regional market is driven by the burgeoning prevalence of gastroparesis, particularly among the diabetic population, which significantly impacts demand for effective treatments. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. Additionally, the gastroparesis drugs market recent developments and advancements, such as high-throughput screening and novel drug delivery systems, enhancing the efficacy and safety profiles of gastroparesis medications are aiding in market expansion. Besides this, the region also benefits from robust healthcare infrastructure and significant investments in research and development, enabling faster introduction of innovative treatments. Moreover, the increasing awareness among healthcare professionals and patients about gastroparesis and its management is strengthening the market growth, leading to earlier diagnosis and more proactive treatment approaches.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, etc.
  • The key gastroparesis drugs companies are actively engaged in several strategic initiatives to advance their position and address the growing demand for effective treatments. They are investing heavily in research and development (R&D) to discover and develop new drugs that target the underlying mechanisms of gastroparesis more effectively. These companies are focusing on innovative drug formulations, including extended-release and novel delivery systems, to enhance the efficacy and patient compliance of treatments. Collaborations and partnerships with research institutions and academic organizations are being pursued to leverage external expertise and resources, which accelerates the development of new therapies. Additionally, leading players are expanding their clinical trial programs to test new drug candidates and gather crucial data to support regulatory approvals. They are also actively seeking regulatory support to expedite the approval process for new treatments, aiming to bring innovative solutions to market more quickly.

Key Questions Answered in This Report

  • 1.What was the size of the global gastroparesis drugs market in 2024?
  • 2.What is the expected growth rate of the global gastroparesis drugs market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4.What are the key factors driving the global gastroparesis drugs market?
  • 5.What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6.What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7.What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8.What are the key regions in the global gastroparesis drugs market?
  • 9.Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players